Perceived Burden of Multidrugs- Resistant Tuberculosis Patients And Their Family: A Systematic Review Of The Qualitative Literature
DOI:
https://doi.org/10.61841/ph6kbx04Keywords:
Family, Multiple Drugs Resistance Tuberculosis, Perceived Burden, Systematic ReviewAbstract
The incidence of Multiple Drugs Resistance Tuberculosis (MDR TB) is still very high. MDR TB treatments require a long period of care that could lead to an impact on MDR TB patients and their families. This study aims at reviewing and synthesizing the perceived burden of MDR TB patients and their families. A literature review was conducted through a search of four journal databases which found eight articles according to the inclusion criteria which were then identified, evaluated and synthesized. A thematic synthesis was conducted of the selected studies. This review identified four major themes related to the perceived burden by MDR TB patients and their family, namely; physical, psychological, social and financial burden. Understanding the difficulties and burdens experienced by MDR TB patients and their families is important in order to choose the appropriate intervention according to the problems that may arise due to MDR TB disease.
Downloads
References
[1] World Health Organization, “Surveillance of drug-resistant TB,” Tuberculosis, 2017.
[2] Kementerian Kesehatan RI, “Tuberkulosis: Temukan Obati Sampai Sembuh,” Pusat Data dan Informasi Kementerian Kesehatan RI, 2017. .
[3] C. G. Boru, T. Shimels, and A. I. Bilalc, “Factors contributing to non-adherence with treatment among
TB patients in Sodo Woreda, Gurage Zone, Southern Ethiopia: A qualitative study,” J. Infect. Public Health, vol. 10, no. 5, pp. 527–533, 2017, doi: https://doi.org/10.1016/j.jiph.2016.11.018.
[4] World Health Organisation, “What is multidrug-resistant tuberculosis (MDR-TB) and how do we control it?,” Online Q&A, 2018. .
[5] M. Bastard et al., “Effects of Treatment Interruption Patterns on Treatment Success Among Patients With Multidrug-Resistant Tuberculosis in Armenia and Abkhazia,” J. Infect. Dis., vol. 211, no. 10, pp. 1607–1615, 2014, doi: https://doi.org/10.1093/infdis/jiu551.
[6] M. D. Morris et al., “Social, Economic, and Psychological Impacts of MDR-TB Treatment in Tijuana, Mexico: A Patient’s Perspective,” Int J Tuberc Lung Dis., vol. 17, no. 7, 2014, doi: 10.5588/ijtld.12.0480.
[7] J. Thomas and A. Harden, “Methods for the thematic synthesis of qualitative research in systematic reviews,” BMC Med Res Methodol., vol. 8, no. 45, 2008, doi: https://doi.org/10.1186/1471-2288-8-45.
[8] M. Loveday et al., “Household context and psychosocial impact of childhood multidrug-resistant tuberculosis in KwaZulu-Natal, South Africa,” Int. J. Tuberc. Lung Dis., vol. 22, no. 1, pp. 40–46, 2018, doi: https://doi.org/10.5588/ijtld.17.0371.
[9] R. D. Deshmukh, D. J. Dhande, K. S. Sachdeva, A. Sreenivas, M. Kumar, A.M.V. Satyanarayana, S. Parmar, and P. K. Moonan, “Patient and provider reported reasons for lost to follow up in MDRTB treatment: A qualitative study from a drug resistant TB Centre in India,” PLoS One, vol. 10, no. 8, p. e0135802, 2015.
[10] K. S. Shringarpure, P. Isaakidis, K. D. Sagili, R. K. Baxi, M. Das, and A. Daftary, “‘ When Treatment Is More Challenging than the Disease’ : A Qualitative Study of MDR-TB Patient Retention,” PLoS One., 2016, doi: 10.1371/journal.pone.0150849.
[11] S. Horter et al., “‘home is where the patient is’: A qualitative analysis of a patient-centred model of care for multi-drug resistant tuberculosis,” BMC Health Serv. Res., vol. 14, no. 21, p. 81, 2014, doi: https://doi.org/10.1186/1472-6963-14-81.
[12] K. Bieh, R. Weigel, and H. Smith, “Hospitalized care for MDR-TB in Port Harcourt, Nigeria: a qualitative study.,” BMC Infect Dis., vol. 17, no. 1, pp. 1–9, 2017, doi: DOI 10.1186/s12879-016-2114-x.
[13] D. Burtscher, V. den Bergh, U. Toktosunov, N. Angmo, N. Samieva, and A. E. Rocillo, “‘My Favourite Day Is Sunday’: Community Perceptions of (Drug-Resistant) Tuberculosis and Ambulatory Tuberculosis Care in Kara Suu District, Osh Province, Kyrgyzstan.,” PLoS One., vol. 11, no. 3, 2016, doi: 10.1371/journal.pone.0152283.
[14] C. Hutchison, M. S. Khan, J. Yoong, X. Lin, and R. J. Coker, “Financial barriers and coping strategies: a qualitative study of accessing multidrug-resistant tuberculosis and tuberculosis care in Yunnan, China,” BMC Public Health, vol. 17, no. 1, pp. 1–11, 2017, doi: 10.1186/s12889-017-4089-y.
[15] M. Morris et al., “Social, economic, and psychological impacts of MDR-TB treatment in Tijuana, Mexico: a patient’s perspective.,” Int J Tuberc Lung Dis., vol. 17, no. 7, pp. 954–60, 2013, doi: 10.5588/ijtld.12.0480.
[16] S. C. Baral, D. K. Karki, and J. N. Newell, “Causes of stigma and discrimination associated with tuberculosis in Nepal: a qualitative study,” BMC Public Health, 2007, doi: https://doi.org/10.1186/1471- 2458-7-211.
[17] A. Courtwright and A. N. Turner, “Tuberculosis and Stigmatization: Pathways and Interventions,”
Public Heal. Rep., vol. 125, no. 4, 2010, doi: 10.1177/00333549101250S407.
[18] I. F. Walker et al., “Depression among multidrug-resistant tuberculosis patients in Punjab, Pakistan: a large cross-sectional study,” Int. J. Tuberc. Lung Dis., vol. 22, no. 7, 2018, doi: https://doi.org/10.5588/ijtld.17.0788.
[19] A. Crampin et al., “Assessment and evaluation of contact as a risk factor for tuberculosis in rural Africa,” Int J Tuberc Lung Dis., vol. 12, no. 6, pp. 612–618, 2008.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
